Updated Perspectives on the Diagnosis and Management of Onychomycosis

References

• Gupta A, Stec N, Summerbell R., et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972–1990. doi:10.1111/jdv.16394
   PubMed Web of Science ®Google Scholar
• Lipner SR, Joseph WS, Vlahovic TC, et al. Therapeutic Recommendations for the treatment of toenail onychomycosis in the US. J Drugs Dermatol. 2021;20(10):1076–1084. doi:10.36849/JDD.6291
   PubMed Web of Science ®Google Scholar
• Lipner SR, Hancock JE, Fleischer AB. The ambulatory care burden of nail conditions in the United States. J Dermatological Treatment. 2021;32(5):517–520. doi:10.1080/09546634.2019.1679337
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835–851. doi:10.1016/j.jaad.2018.03.062
   PubMed Web of Science ®Google Scholar
• Sergeev A, Ivanov O, Sergeev Y, et al. Epidemiology of onychomycosis in modern Russia: incidence is growing. Mycoses. 2002;45(S2):56. doi:10.1111/j.1439-0507.2002.tb04771.x
   PubMed Web of Science ®Google Scholar
• Burzykowski T, Molenberghs G, Abeck D, et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses. 2003;46(11‐12):496–505. doi:10.1046/j.0933-7407.2003.00933.x
   PubMed Web of Science ®Google Scholar
• Ioannidou D, Maraki S, Krasagakis S, et al. The epidemiology of onychomycoses in Crete, Greece, between 1992 and 2001. J Eur Acad Dermatol Venereol. 2006;20(2):170–174. doi:10.1111/j.1468-3083.2006.01412.x
   PubMed Web of Science ®Google Scholar
• Vélez A, Linares MJ, Fenández-Roldán JC, et al. Study of onychomycosis in Cordoba, Spain: prevailing fungi and pattern of infection. Mycopathologia. 1997;137(1):1–8. doi:10.1023/A:1006874303991
   PubMed Web of Science ®Google Scholar
• Murray SC, Dawber RP. Onychomycosis of toenails: orthopaedic and podiatric considerations. Australasian j Dermatol. 2002;43(2):105–112. doi:10.1046/j.1440-0960.2002.t01-1-00570.x
   PubMedGoogle Scholar
• Scher R, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(s65):5–9. doi:10.1046/j.1365-2133.149.s65.5.x
   PubMed Web of Science ®Google Scholar
• Carrillo-Meléndrez H, Ortega-Hernández E, Granados J, et al. Role of HLA-DR alleles to increase genetic susceptibility to onychomycosis in nail psoriasis. Skin Appendage Disorders. 2016;2(1–2):22–25. doi:10.1159/000446444
   PubMedGoogle Scholar
• Faergemann J, Correia O, Nowicki R, et al. Genetic predisposition–understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19:17–19. doi:10.1111/j.1468-3083.2005.01283.x
   PubMed Web of Science ®Google Scholar
• Jazdarehee A, Malekafzali L, Lee J, et al. Transmission of onychomycosis and dermatophytosis between household members: a scoping review. J Fungi. 2022;8(1):60. doi:10.3390/jof8010060
   Web of Science ®Google Scholar
• Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol. 1997;133(9):1172–1173. doi:10.1001/archderm.1997.03890450124022
   PubMed Web of Science ®Google Scholar
• Bunyaratavej S, Srinonprasert V, Kiratiwongwan R, et al. Onychomycosis in older adults: the age and associated factors affecting the complete cure rate. Australasian J Dermatol. 2022;63(1):74–80. doi:10.1111/ajd.13686
   PubMed Web of Science ®Google Scholar
• Thomas J, Jacobson G, Narkowicz C, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519. doi:10.1111/j.1365-2710.2009.01107.x
   PubMed Web of Science ®Google Scholar
• Solís‐Arias MP, García‐Romero MT. Onychomycosis in children. Int J Dermatol. 2017;56(2):123–130. doi:10.1111/ijd.13392
   PubMed Web of Science ®Google Scholar
• Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38(5):702–704. doi:10.1016/S0190-9622(98)70199-9
   PubMed Web of Science ®Google Scholar
• Stewart CR, Algu L, Kamran R, et al. Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: a systematic review. J Am Acad Dermatol. 2021;85(5):1227–1239. doi:10.1016/j.jaad.2020.05.143
   PubMed Web of Science ®Google Scholar
• Kang R, Lipner S. Evaluation of Onychomycosis Information on the Internet. J Drugs Dermatol. 2019;18(5):484–487.
   PubMed Web of Science ®Google Scholar
• Svejgaard E, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses. 2004;47(3‐4):131–135. doi:10.1111/j.1439-0507.2004.00968.x
   PubMed Web of Science ®Google Scholar
• Pérez‐Cantero A, Guarro J. Sarocladium and Acremonium infections: new faces of an old opportunistic fungus. Mycoses. 2020;63(11):1203–1214. doi:10.1111/myc.13169
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010;28(2):151–159. doi:10.1016/j.clindermatol.2009.12.006
   PubMed Web of Science ®Google Scholar
• Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494–502. doi:10.1016/j.jaad.2011.02.038
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Hajjeh R, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641–648. doi:10.1067/mjd.2000.107754
   PubMed Web of Science ®Google Scholar
• Jayatilake J, Tilakaratne W, Panagoda G. Candidal onychomycosis: a mini-review. Mycopathologia. 2009;168(4):165–173. doi:10.1007/s11046-009-9212-x
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta G, Jain H, et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices. J Eur Acad Dermatol Venereol. 2016;30(9):1567–1572. doi:10.1111/jdv.13677
   PubMed Web of Science ®Google Scholar
• Garcia-Martos P, Hernández-Molina JM, Galán F. Isolation of Hanseniaspora uvarum (Kloeckera apiculata) in humans. Mycopathologia. 1998;144(2):73–75. doi:10.1023/A:1006900909455
   PubMed Web of Science ®Google Scholar
• Sánchez-Cárdenas CD, Vega-Sánchez DC, González-Suárez TR, et al. Onychomycosis caused by kloeckera apiculata: a case report in a patient with multiple sclerosis. Skin Appendage Disorders. 2022;8(1):49–52. doi:10.1159/000518046
   PubMed Web of Science ®Google Scholar
• Gupta AK, Mays RR, Versteeg SG, et al. Global perspectives for the management of onychomycosis. Int J Dermatol. 2019;58(10):1118–1129. doi:10.1111/ijd.14346
   PubMed Web of Science ®Google Scholar
• Rafat Z, Hashemi S, Saboor-Yaraghi -A-A, et al. A systematic review and meta-analysis on the epidemiology, casual agents and demographic characteristics of onychomycosis in Iran. J Mycol Med. 2019;29(3):265–272. doi:10.1016/j.mycmed.2019.05.004
   PubMed Web of Science ®Google Scholar
• Raghavendra K, Yadav D, Kumar A, et al. The nondermatophyte molds: emerging as leading cause of onychomycosis in south-east Rajasthan. Indian Dermatol Online J. 2015;6(2):92. doi:10.4103/2229-5178.153010
   PubMedGoogle Scholar
• Leelavathi M, Tzar M, Adawiah J. Common microorganisms causing onychomycosis in tropical climate. Sains Malaysiana. 2012;41(6):697–700.
   Web of Science ®Google Scholar
• Gupta AK, Foley KA. Evidence for biofilms in onychomycosis. Giornale italiano di dermatologia e venereologia. 2018;154(1):50–55. doi:10.23736/S0392-0488.18.06001-7
   PubMed Web of Science ®Google Scholar
• Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms. Crit Rev Microbiol. 2009;35(4):340–355. doi:10.3109/10408410903241436
   PubMed Web of Science ®Google Scholar
• Percival SL, Emanuel C, Cutting KF, et al. Microbiology of the skin and the role of biofilms in infection. Int Wound J. 2012;9(1):14–32. doi:10.1111/j.1742-481X.2011.00836.x
   PubMed Web of Science ®Google Scholar
• Borghi E, Borgo F, Morace G. Fungal biofilms: update on resistance. Fungal Biofilms Related Infections. 2016;1:37–47.
   Web of Science ®Google Scholar
• Gupta AK, Daigle D, Carviel JL. The role of biofilms in onychomycosis. J Am Acad Dermatol. 2016;74(6):1241–1246. doi:10.1016/j.jaad.2016.01.008
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: diagnosis and therapy. Med Mycol. 2015;2;28.
   Google Scholar
• Gupta AK, Mays RR, Versteeg SG, et al. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther. 2018;16(12):929–938. doi:10.1080/14787210.2018.1544891
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: current and investigational therapies. Cutis. 2014;94(6):548.
   Google Scholar
• Ricardo JW, Lipner SR. Safety of current therapies for onychomycosis. Expert Opin Drug Saf. 2020;19(11):1395–1408. doi:10.1080/14740338.2020.1829592
   PubMed Web of Science ®Google Scholar
• Bedaiwy MY, Metwally M-A-E-A, Elzawawy NA, et al. Epidemiology, causative agents and clinical features of onychomycosis in El-Gharbia governorate. Egypt J Botany. 2017;57(7):187–196. doi:10.21608/ejbo.2017.965.1080
   Web of Science ®Google Scholar
• Kaur R, Kashyap B, Bhalla P. Onychomycosis-epidemiology, diagnosis and management. Indian J Med Microbiol. 2008;26(2):108–116. doi:10.1016/S0255-0857(21)01924-1
   PubMed Web of Science ®Google Scholar
• Dubljanin E, Dzamic A, Vujcic I, et al. Correlation of clinical characteristics, by calculation of SCIO index, with the laboratory diagnosis of onychomycosis. Br J Microbiol. 2022;53(1):221–229. doi:10.1007/s42770-021-00676-z
   PubMed Web of Science ®Google Scholar
• Piraccini B, Balestri R, Starace M, et al. Nail digital dermoscopy (onychoscopy) in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol. 2013;27(4):509–513. doi:10.1111/j.1468-3083.2011.04323.x
   PubMed Web of Science ®Google Scholar
• Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg. 2016;33(3):305–318. doi:10.1016/j.cpm.2016.02.001
   PubMed Web of Science ®Google Scholar
• Jesús-Silva MA, Fernández-Martínez R, Roldán-Marín R, et al. Dermoscopic patterns in patients with a clinical diagnosis of onychomycosis—results of a prospective study including data of potassium hydroxide (KOH) and culture examination. Dermatol Practical Conceptual. 2015;5(2):39. doi:10.5826/dpc.0502a05
   PubMedGoogle Scholar
• De Crignis G, Valgas N, Rezende P, et al. Dermatoscopy of onychomycosis. Int J Dermatol. 2014;53(2):e97–e99. doi:10.1111/ijd.12104
   PubMed Web of Science ®Google Scholar
• Finch J, Arenas R, Baran R. Fungal melanonychia. J Am Acad Dermatol. 2012;66(5):830–841. doi:10.1016/j.jaad.2010.11.018
   PubMed Web of Science ®Google Scholar
• Ohn J, Choe YS, Park J, et al. Dermoscopic patterns of fungal melanonychia: a comparative study with other causes of melanonychia. J Am Acad Dermatol. 2017;76(3):488–493. e2. doi:10.1016/j.jaad.2016.08.013
   PubMed Web of Science ®Google Scholar
• Gupta AK, Versteeg SG, Shear NH. Confirmatory testing prior to initiating onychomycosis therapy is cost-effective. J Cutan Med Surg. 2018;22(2):129–141. doi:10.1177/1203475417733461
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis–a small step for quality of care. Curr Med Res Opin. 2016;32(5):865–867. doi:10.1185/03007995.2016.1147026
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Confirmatory testing for onychomycosis. JAMA dermatol. 2016;152(7):847. doi:10.1001/jamadermatol.2016.0785
   PubMed Web of Science ®Google Scholar
• Dermatology AAo. Ten Things Physicians and Patients Should Question 2021; 2022. Available from: https://www.choosingwisely.org/societies/american-academy-of-dermatology/. Accessed September 9, 2022.
   Google Scholar
• Geizhals S, Cooley V, Lipner SR. Diagnostic testing for onychomycosis: a retrospective study over 17 years. J Am Acad Dermatol. 2020;83(1):239–241. doi:10.1016/j.jaad.2019.12.019
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N, Catalano V. A second look at efficacy criteria for onychomycosis: clinical and mycological cure. Br J Dermatol. 2014;170(1):182–187. doi:10.1111/bjd.12594
   PubMed Web of Science ®Google Scholar
• Blank N, Lipner SR. A contrasting dark background for nail sampling. Cutis. 2021;108:341. doi:10.12788/cutis.0403
   PubMed Web of Science ®Google Scholar
• Lipner SR, Ghannoum M, Hinshaw MA, et al. Deferring nail mycological sampling during the covid-19 pandemic: recommendations from a multidisciplinary panel of nail specialists. Skin Appendage Disorders. 2022;8(3):241–244. doi:10.1159/000520628
   Web of Science ®Google Scholar
• Gupta AK, Simpson FC. Diagnosing onychomycosis. Clin Dermatol. 2013;31(5):540–543. doi:10.1016/j.clindermatol.2013.06.009
   PubMed Web of Science ®Google Scholar
• Lilly KK, Koshnick RL, Grill JP, et al. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol. 2006;55(4):620–626. doi:10.1016/j.jaad.2006.03.033
   PubMed Web of Science ®Google Scholar
• Bombace F, Iovene MR, Galdiero M, et al. Non‐dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses. 2016;59(9):558–565. doi:10.1111/myc.12504
   PubMed Web of Science ®Google Scholar
• Baran R, de Berker DA, Holzberg M, et al. Baran and Dawber’s Diseases of the Nails and Their Management. John Wiley & Sons; 2012.
   Google Scholar
• Mahoney JM, Bennet J, Olsen B. The diagnosis of onychomycosis. Dermatol Clin. 2003;21(3):463–467. doi:10.1016/S0733-8635(03)00035-4
   PubMed Web of Science ®Google Scholar
• Sidiq F, Hoostal M, Rogers SO. Rapid identification of fungi in culture-negative clinical blood and respiratory samples by DNA sequence analyses. BMC Res Notes. 2016;9(1):1–8. doi:10.1186/s13104-016-2097-0
   PubMedGoogle Scholar
• Alberhasky RC. Laboratory diagnosis of onychomycosis. Clin Podiatr Med Surg. 2004;21(4):565–578. doi:10.1016/j.cpm.2004.06.001
   PubMedGoogle Scholar
• Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol. 2003;49(2):193–197. doi:10.1067/S0190-9622(03)01480-4
   PubMed Web of Science ®Google Scholar
• D’Hue Z, Perkins SM, Billings SD. GMS is superior to PAS for diagnosis of onychomycosis. J Cutan Pathol. 2008;35(8):745–747. doi:10.1111/j.1600-0560.2007.00890.x
   PubMed Web of Science ®Google Scholar
• Smith MB, McGinnis MR. Diagnostic Histopathology. Diagnosis and Treatment of Human Mycoses. Springer; 2008:37–51.
   Google Scholar
• Verrier J, Monod M. Diagnosis of dermatophytosis using molecular biology. Mycopathologia. 2017;182(1):193–202. doi:10.1007/s11046-016-0038-z
   PubMed Web of Science ®Google Scholar
• Bock M, Maiwald M, Kappe R, et al. Polymerase chain reaction‐based detection of dermatophyte DNA with a fungus‐specific primer system: Nachweis von Dermatophyten‐DNA durch Polymerase‐Ketten‐Reaktion mit einem pilzspezifischen Primersystem. Mycoses. 1994;37(3‐4):79–84. doi:10.1111/j.1439-0507.1994.tb00781.x
   PubMedGoogle Scholar
• Baek SC, Chae HJ, Houh D, et al. Detection and differentiation of causative fungi of onychomycosis using PCR amplification and restriction enzyme analysis. Int J Dermatol. 1998;37(9):682–686. doi:10.1046/j.1365-4362.1998.00517.x
   PubMed Web of Science ®Google Scholar
• Gupta AK, Nakrieko K-A. Onychomycosis infections: do polymerase chain reaction and culture reports agree? J Am Podiatr Med Assoc. 2017;107(4):280–286. doi:10.7547/15-136
   PubMed Web of Science ®Google Scholar
• Verrier J, Pronina M, Peter C, et al. Identification of infectious agents in onychomycoses by PCR-terminal restriction fragment length polymorphism. J Clin Microbiol. 2012;50(3):553–561. doi:10.1128/JCM.05164-11
   PubMed Web of Science ®Google Scholar
• Kondori N, Abrahamsson A-L, Ataollahy N, et al. Comparison of a new commercial test, Dermatophyte-PCR kit, with conventional methods for rapid detection and identification of Trichophyton rubrum in nail specimens. Med Mycol. 2010;48(7):1005–1008. doi:10.3109/13693781003743130
   PubMed Web of Science ®Google Scholar
• Petinataud D, Berger S, Ferdynus C, et al. Optimising the diagnostic strategy for onychomycosis from sample collection to fungal identification evaluation of a diagnostic kit for real‐time PCR. Mycoses. 2016;59(5):304–311. doi:10.1111/myc.12471
   PubMed Web of Science ®Google Scholar
• Gustafson E, Bakotic W, Bennett L, et al. DNA-based detection for onychomycosis correlates better to histopathology than does fungal culture. Dermatol Online J. 2019;25(7). doi:10.5070/D3257044800.
   PubMedGoogle Scholar
• Kim YJ, Han SS, Yang HJ, et al. Prospective, comparative evaluation of a deep neural network and dermoscopy in the diagnosis of onychomycosis. PLoS One. 2020;15(6):e0234334. doi:10.1371/journal.pone.0234334
   PubMed Web of Science ®Google Scholar
• Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. nature. 2017;542(7639):115–118. doi:10.1038/nature21056
   PubMed Web of Science ®Google Scholar
• Lu J, Kazmierczak E, Manton JH, et al. Automatic segmentation of scaling in 2-D psoriasis skin images. IEEE Trans Med Imaging. 2012;32(4):719–730. doi:10.1109/TMI.2012.2236349
   PubMed Web of Science ®Google Scholar
• Moreau A, Anderer P, Ross M, et al. Detection of nocturnal scratching movements in patients with atopic dermatitis using accelerometers and recurrent neural networks. IEEE j Biomedical Health Informatics. 2017;22(4):1011–1018. doi:10.1109/JBHI.2017.2710798
   PubMed Web of Science ®Google Scholar
• Phillips M, Marsden H, Jaffe W, et al. Assessment of accuracy of an artificial intelligence algorithm to detect melanoma in images of skin lesions. JAMA network open. 2019;2(10):e1913436–e1913436. doi:10.1001/jamanetworkopen.2019.13436
   PubMed Web of Science ®Google Scholar
• Brinker TJ, Hekler A, Enk AH, et al. Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. Eur J Cancer. 2019;113:47–54. doi:10.1016/j.ejca.2019.04.001
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Otomo Y, Ogata Y, et al. Deep‐learning‐based, computer‐aided classifier developed with a small dataset of clinical images surpasses board‐certified dermatologists in skin tumour diagnosis. Br J Dermatol. 2019;180(2):373–381. doi:10.1111/bjd.16924
   PubMed Web of Science ®Google Scholar
• Zhu X, Zheng B, Cai W, et al. Deep learning‐based diagnosis models for onychomycosis in dermoscopy. Mycoses. 2022;65(4):466–472. doi:10.1111/myc.13427
   PubMed Web of Science ®Google Scholar
• Han SS, Park GH, Lim W, et al. Deep neural networks show an equivalent and often superior performance to dermatologists in onychomycosis diagnosis: automatic construction of onychomycosis datasets by region-based convolutional deep neural network. PLoS One. 2018;13(1):e0191493. doi:10.1371/journal.pone.0191493
   PubMed Web of Science ®Google Scholar
• Decroos F, Springenberg S, Lang T, et al. A deep learning approach for histopathological diagnosis of onychomycosis: not inferior to analogue diagnosis by histopathologists. Acta Derm Venereol. 2021;101(8):adv00532–adv00532. doi:10.2340/00015555-3893
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853–867. doi:10.1016/j.jaad.2018.05.1260
   PubMed Web of Science ®Google Scholar
• Lipner SR. Pharmacotherapy for onychomycosis: new and emerging treatments. Expert Opin Pharmacother. 2019;20(6):725–735. doi:10.1080/14656566.2019.1571039
   PubMed Web of Science ®Google Scholar
• Ameen M, Lear J, Madan V, et al. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171(5):937–958. doi:10.1111/bjd.13358
   PubMed Web of Science ®Google Scholar
• Falotico JM, Lapides R, Lipner SR. Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: a Systematic Review of Onychomycosis Clinical Trials. J Fungi. 2022;8(3):279. doi:10.3390/jof8030279
   Web of Science ®Google Scholar
• Chang MJ, Qiu Y, Lipner SR. Race reporting and representation in onychomycosis clinical trials: a systematic review. Mycoses. 2021;64(8):954–966. doi:10.1111/myc.13262
   PubMed Web of Science ®Google Scholar
• Vikas A, Rashmin P, Mrunali P, et al. Mechanistic insights of formulation approaches for the treatment of nail infection: conventional and novel drug delivery approaches. AAPS PharmSciTech. 2020;21(2):1–12. doi:10.1208/s12249-019-1591-9
   Web of Science ®Google Scholar
• Aslam R, Hussain T, Yousaf AM, et al. Onychomycosis: current understanding and strategies for enhancing drug delivery into human nail tissue. Curr Drug Res Rev Formerly. 2021;13(1):25–35. doi:10.2174/2589977512666200731171505
   PubMedGoogle Scholar
• Burkharta CN, Burkhart CG, Gupta AK. Dermatophytoma: recalcitrance to treatment because of existence of fungal biofilm. J Am Acad Dermatol. 2002;47(4):629–631. doi:10.1067/mjd.2002.124699
   PubMed Web of Science ®Google Scholar
• Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441–472. doi:10.2165/00003088-200140060-00005
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals North America, LLC. Gris-Peg (griseofulvin) ultramicrosize [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America, LLC; 2016.
   Google Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol. 1994;30(6):911–933. doi:10.1016/s0190-9622(94)70112-1
   PubMed Web of Science ®Google Scholar
• Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. J Dermatological Treatment. 2021;32(7):783–787. doi:10.1080/09546634.2019.1708242
   PubMed Web of Science ®Google Scholar
• Ishack S, Miller RC, Lipner SR. Insights into the “fear factor” regarding terbinafine-associated hepatoxicity in an assessment of online information. J Am Acad Dermatol. 2022;86(6):e269–e271. doi:10.1016/j.jaad.2022.02.006
   PubMed Web of Science ®Google Scholar
• Novartis. Highlights of Prescribing Information 2012; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf. Accessed September 9, 2022.
   Google Scholar
• Kramer O, Albrecht J. Clinical presentation of terbinafine‐induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic. Br J Dermatol. 2017;177(5):1279–1284. doi:10.1111/bjd.15854
   PubMed Web of Science ®Google Scholar
• Wang Y, Geizhals S, Lipner SR. Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis. J Am Acad Dermatol. 2021;84(2):497–499. doi:10.1016/j.jaad.2020.04.172
   PubMed Web of Science ®Google Scholar
• Stolmeier DA, Stratman HB, McIntee TJ, et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections. JAMA dermatol. 2018;154(12):1409–1416. doi:10.1001/jamadermatol.2018.3578
   PubMed Web of Science ®Google Scholar
• Kao WY, Su CW, Huang YS, et al. Risk of oral antifungal agent‐induced liver injury in T aiwanese. Br J Clin Pharmacol. 2014;77(1):180–189. doi:10.1111/bcp.12178
   PubMed Web of Science ®Google Scholar
• Wang Y, Lipner SR. Retrospective analysis of abnormal laboratory test results in pediatric patients prescribed terbinafine for superficial fungal infections. J Am Acad Dermatol. 2021;85(4):1042–1044. doi:10.1016/j.jaad.2021.01.073
   PubMed Web of Science ®Google Scholar
• Patel D, Castelo-Soccio LA, Rubin AI, et al. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis. JAMA dermatol. 2017;153(12):1326–1327. doi:10.1001/jamadermatol.2017.4483
   PubMed Web of Science ®Google Scholar
• Warshaw EM. Evaluating costs for onychomycosis treatments: a practitioner’s perspective. J Am Podiatr Med Assoc. 2006;96(1):38–52. doi:10.7547/0960038
   PubMed Web of Science ®Google Scholar
• Gupta A, Paquet M, Simpson F, et al. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta‐analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27(3):267–272. doi:10.1111/j.1468-3083.2012.04584.x
   PubMed Web of Science ®Google Scholar
• Gupta A, Stec N, Bamimore M, et al. The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2020;34(3):580–588. doi:10.1111/jdv.16101
   PubMed Web of Science ®Google Scholar
• Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 1993;28(5):S28–S34. doi:10.1016/S0190-9622(09)80305-8
   PubMed Web of Science ®Google Scholar
• Korting HC, Schöllmann C. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. JDDG. 2009;7(1):11–19.
   Google Scholar
• Elewski B, Pariser D, Rich P, et al. Current and emerging options in the treatment of onychomycosis. Int J Med. 2013;32(2):9–12.
   Google Scholar
• Sigurgeirsson B, Paul C, Curran D, et al. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br j dermatol. 2002;147(6):1241–1243. doi:10.1046/j.1365-2133.2002.05035.x
   PubMed Web of Science ®Google Scholar
• Gupta A, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol. 2002;16(6):579–586. doi:10.1046/j.1468-3083.2002.00589.x
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;44(3):479–484. doi:10.1067/mjd.2001.110874
   PubMed Web of Science ®Google Scholar
• Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol. 2000;39(6):401–411. doi:10.1046/j.1365-4362.2000.00964.x
   PubMed Web of Science ®Google Scholar
• Gupta AK, Drummond-Main C, Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. J Dermatological Treatment. 2013;24(1):75–80. doi:10.3109/09546634.2012.703308
   PubMed Web of Science ®Google Scholar
• Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother. 2009;43(10):1684–1691. doi:10.1345/aph.1M165
   PubMed Web of Science ®Google Scholar
• Lin K, Lipner SR. Mobile phone reminders for onychomycosis medication adherence. J Am Acad Dermatol. 2019;80(5):e105–e107. doi:10.1016/j.jaad.2018.11.010
   PubMed Web of Science ®Google Scholar
• Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6):S77–S86. doi:10.1016/S0190-9622(98)70490-6
   PubMed Web of Science ®Google Scholar
• Muńoz P, Moreno S, Berenguer J, et al. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1991;151(5):1020–1021. doi:10.1001/archinte.1991.00400050150032
   PubMedGoogle Scholar
• Brammer K, Farrow PR, Faulkner J. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Supplement_3):S318–S326. doi:10.1093/clinids/12.Supplement_3.S318
   PubMedGoogle Scholar
• Falotico JM, Wang Y, Rahman U, et al. Increased fluconazole usage by dermatologists in the Medicare provider utilization and payment database, 2014-2019. J Am Acad Dermatol. 2022;S0190(22):974.
   Google Scholar
• Kreijkamp‐Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Sys Rev. 2017;2017(7). doi:10.1002/14651858.CD010031.pub2.
   Web of Science ®Google Scholar
• Elewski B, Pollak R, Ashton S, et al. A randomized, placebo‐and active‐controlled, parallel‐group, multicentre, investigator‐blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–398. doi:10.1111/j.1365-2133.2011.10660.x
   PubMed Web of Science ®Google Scholar
• Noguchi H, Matsumoto T, Kimura U, et al. Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole. J Dermatol. 2019;46(10):911–913. doi:10.1111/1346-8138.15024
   PubMed Web of Science ®Google Scholar
• Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L‐lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double‐blind, randomized phase III study. J Dermatol. 2018;45(10):1151–1159. doi:10.1111/1346-8138.14607
   PubMed Web of Science ®Google Scholar
• Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol. 2021. doi:10.1111/ijd.15999
   Web of Science ®Google Scholar
• Elewski B, Brand S, Degenhardt T, et al. A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2021;184(2):270–280. doi:10.1111/bjd.19224
   PubMed Web of Science ®Google Scholar
• Gupta AK, Versteeg SG, Shear NH. Common drug-drug interactions in antifungal treatments for superficial fungal infections. Expert Opin Drug Metab Toxicol. 2018;14(4):387–398. doi:10.1080/17425255.2018.1461834
   PubMed Web of Science ®Google Scholar
• Costa-Orlandi CB, Martinez LR, Bila NM, et al. Nitric Oxide-Releasing Nanoparticles Are Similar to Efinaconazole in Their Capacity to Eradicate Trichophyton rubrum Biofilms. Front Cell Infect Microbiol. 2021;1;665.
   Google Scholar
• Davies-Strickleton H, Cook J, Hannam S, et al. Assessment of the nail penetration of antifungal agents, with different physico-chemical properties. PLoS One. 2020;15(2):e0229414. doi:10.1371/journal.pone.0229414
   PubMed Web of Science ®Google Scholar
• Thatai P, Sapra B. Transungual delivery: deliberations and creeds. Int J Cosmet Sci. 2014;36(5):398–411. doi:10.1111/ics.12142
   PubMed Web of Science ®Google Scholar
• Angelo T, Borgheti-Cardoso LN, Gelfuso GM, et al. Chemical and physical strategies in onychomycosis topical treatment: a review. Med Mycol. 2017;55(5):461–475. doi:10.1093/mmy/myw084
   PubMed Web of Science ®Google Scholar
• Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharmaceutical Nanotechnol. 2019;7(1):24–38. doi:10.2174/2211738507666190228104031
   PubMedGoogle Scholar
• Wang Y, Lipner SR. Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration. Arch Dermatol Res. 2020;312(8):581–586. doi:10.1007/s00403-020-02044-7
   PubMed Web of Science ®Google Scholar
• Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol. 2010;9(9):1109–1113.
   PubMed Web of Science ®Google Scholar
• Belenky P, Camacho D, Collins JJ. Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep. 2013;3(2):350–358. doi:10.1016/j.celrep.2012.12.021
   PubMed Web of Science ®Google Scholar
• Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4):S57–S69. doi:10.1067/mjd.2000.109072
   PubMed Web of Science ®Google Scholar
• Dermik Laboratories. Penlac Nail Lacquer (Ciclopirox) Topical Solution, 8% [Package Insert]. Bridgewater, NJ: Dermik Laboratories; 2005. Available from: http://products.sanofi.us/penlac/penlac.html. Accessed September 9, 2022.
   Google Scholar
• Foley K, Gupta AK, Versteeg S, et al. Topical and device‐based treatments for fungal infections of the toenails. Cochrane Database Sys Rev. 2020; 1. doi:10.1002/14651858.CD012093.pub2
   PubMed Web of Science ®Google Scholar
• Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4):S70–S80. doi:10.1067/mjd.2000.109071
   PubMed Web of Science ®Google Scholar
• Lipner SR, Ko D. Optimizing topical therapy for onychomycosis: the importance of patient education. Cutis. 2018;102(6):389–390.
   PubMed Web of Science ®Google Scholar
• Wang C, Cantrell W, Canavan T, et al. Successful treatment of dermatophytomas in 19 patients using efinaconazole 10% solution. Skin Appendage Disorders. 2019;5(5):304–308. doi:10.1159/000495042
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600–608. doi:10.1016/j.jaad.2012.10.013
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17(4):611–618. doi:10.1517/14656566.2016.1146687
   PubMed Web of Science ®Google Scholar
• Zeichner JA, Gold LS, Korotzer A. Penetration of (14C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail Polish. J Clin Aesthet Dermatol. 2014;7(9):34.
   PubMedGoogle Scholar
• Vlahovic TC, Coronado D, Chanda S, et al. Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole. J Drugs Dermatol. 2016;15(1):89–94.
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail. Expert Rev Clin Pharmacol. 2015;8(6):719–731. doi:10.1586/17512433.2015.1083418
   PubMed Web of Science ®Google Scholar
• Canavan TN, Bevans SL, Cantrell WC, et al. Single-center, prospective, blinded study comparing the efficacy and compatibility of efinaconazole 10% solution in treating onychomycosis with and without concurrent nail Polish use. Skin Appendage Disorders. 2019;5(1):9–12. doi:10.1159/000488369
   Web of Science ®Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. science. 2007;316(5832):1759–1761. doi:10.1126/science.1142189
   PubMed Web of Science ®Google Scholar
• Fougera Pharmaceuticals. Kerydin (Tavaborole) Topical Solution, 5% [Package Insert]. Melville, NY: Fougera Pharmaceuticals; 2005. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid51ae61072-bca0-43f0-a741-07bda2d50c87. Accessed September 9, 2022.
   Google Scholar
• Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur j Pharmaceutical Sci. 2004;21(4):471–477. doi:10.1016/j.ejps.2003.11.008
   PubMed Web of Science ®Google Scholar
• Tracey Vlahovic D, Zane LT. In vitro nail penetration of tavaborole topical solution, 5%, through nail Polish on ex vivo human fingernails. J Drugs Dermatol. 2015;14(7):675–678.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73(1):62–69. doi:10.1016/j.jaad.2015.04.010
   PubMed Web of Science ®Google Scholar
• Feng X, Xiong X, Ran Y. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: a meta‐analysis and systematic review. Dermatol Ther. 2017;30(3):e12457. doi:10.1111/dth.12457
   Web of Science ®Google Scholar
• Haria M, Bryson HM. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. J Med. 1995:58.
   Google Scholar
• Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology. 1992;184(Suppl. 1):21–24. doi:10.1159/000247612
   PubMed Web of Science ®Google Scholar
• Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17(s1):41–43. doi:10.1111/j.1365-2230.1992.tb00277.x
   PubMed Web of Science ®Google Scholar
• Tabara K, Szewczyk AE, Bienias W, et al. Amorolfine vs. ciclopirox–lacquers for the treatment of onychomycosis. Adv Dermatol Allergology. 2015;32(1):40–45. doi:10.5114/pdia.2014.40968
   PubMed Web of Science ®Google Scholar
• Mensing H, Polak‐Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month’s treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol. 1992;17:29–32. doi:10.1111/j.1365-2230.1992.tb00274.x
   PubMed Web of Science ®Google Scholar
• Gupta AK, Surprenant MS, Kempers SE, et al. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: a randomized, multicenter, double-blind, vehicle-controlled Phase 3 study. J Am Acad Dermatol. 2021;85(1):95–104. doi:10.1016/j.jaad.2020.06.055
   PubMed Web of Science ®Google Scholar
• Monti D, Herranz U, Dal BL, et al. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects. J Eur Acad Dermatol Venereol. 2013;27(2):e153–e158. doi:10.1111/j.1468-3083.2012.04529.x
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Hartmane I, Derveniece A, et al. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator. Skin Appendage Disorders. 2015;1(3):134–140. doi:10.1159/000441569
   PubMedGoogle Scholar
• Halteh P, Scher RK, Lipner SR. Over-the-counter and natural remedies for onychomycosis: do they really work. Cutis. 2016;98(5):E16–e25.
   PubMedGoogle Scholar
• Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev. 2006;19(1):50–62. doi:10.1128/CMR.19.1.50-62.2006
   PubMed Web of Science ®Google Scholar
• D’auria F, Laino L, Strippoli V, et al. In vitro activity of tea tree oil against Candida albicans mycelial conversion and other pathogenic fungi. J Chemother. 2001;13(4):377–383. doi:10.1179/joc.2001.13.4.377
   PubMed Web of Science ®Google Scholar
• Hammer K, Carson C, Riley T. Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae. J Antimicrobial Chemother. 2004;53(6):1081–1085. doi:10.1093/jac/dkh243
   PubMed Web of Science ®Google Scholar
• Hammer K, Carson C, Riley T. Melaleuca alternifolia (tea tree) oil inhibits germ tube formation by Candida albicans. Med Mycol. 2000;38(5):354–362. doi:10.1080/mmy.38.5.354.361
   Web of Science ®Google Scholar
• Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: melaleuca alternifolia (tea tree) oil and clotrimazole. J Family Practice. 1994;38(6):601–606.
   PubMed Web of Science ®Google Scholar
• Syed T, Qureshi Z, Ali S, et al. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop Med Int Health. 1999;4(4):284–287. doi:10.1046/j.1365-3156.1999.00396.x
   PubMed Web of Science ®Google Scholar
• Derby R, Rohal P, Jackson C, et al. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Family Med. 2011;24(1):69–74. doi:10.3122/jabfm.2011.01.100124
   PubMed Web of Science ®Google Scholar
• Snell M, Klebert M, Önen NF, et al. A novel treatment for onychomycosis in people living with HIV infection: vicks VapoRub™ is effective and safe. J Assoc Nurses AIDS Care. 2016;27(1):109–113. doi:10.1016/j.jana.2015.10.004
   PubMed Web of Science ®Google Scholar
• Auvinen T, Tiihonen R, Soini M, et al. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator‐blinded, parallel‐group clinical trial. Br J Dermatol. 2015;173(4):940–948. doi:10.1111/bjd.13934
   PubMed Web of Science ®Google Scholar
• Argueta A, Cano Asseleih LM, Rodarte García ME. Atlas de las plantas de la medicina tradicional mexicana. 1994: (C QK 99. M6. A84 1994).
   Google Scholar
• Romero-Cerecero O, Rojas G, Navarro V, et al. Effectiveness and tolerability of a standardized extract from Ageratina pichinchensis on patients with tinea pedis: an explorative pilot study controlled with ketoconazole. Planta Med. 2006;72(14):1257–1261. doi:10.1055/s-2006-951694
   PubMed Web of Science ®Google Scholar
• Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, et al. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med. 2008;74(12):1430–1435. doi:10.1055/s-2008-1081338
   PubMed Web of Science ®Google Scholar
• Bocci V. Biological and clinical effects of ozone. Has ozone therapy a future in medicine? Br J Biomed Sci. 1999;56(4):270.
   PubMed Web of Science ®Google Scholar
• Menéndez S, Falcón L, Maqueira Y. Therapeutic efficacy of topical OLEOZON® in patients suffering from onychomycosis. Mycoses. 2011;54(5):e272–e277. doi:10.1111/j.1439-0507.2010.01898.x
   PubMed Web of Science ®Google Scholar
• Gupta A, Versteeg S. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J Eur Acad Dermatol Venereol. 2017;31(7):1111–1118. doi:10.1111/jdv.14212
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M. A retrospective chart review of the clinical efficacy of Nd: YAG 1064-nm laser for toenail onychomycosis. J Dermatological Treatment. 2015;26(4):376–378. doi:10.3109/09546634.2014.975671
   PubMed Web of Science ®Google Scholar
• Hay R. Therapy of skin, hair and nail fungal infections. J Fungi. 2018;4(3):99. doi:10.3390/jof4030099
   Web of Science ®Google Scholar
• Hollmig ST, Rahman Z, Henderson MT, et al. Lack of efficacy with 1064-nm neodymium: yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;70(5):911–917. doi:10.1016/j.jaad.2013.12.024
   PubMed Web of Science ®Google Scholar
• Carney C, Cantrell W, Warner J, et al. Treatment of onychomycosis using a submillisecond 1064-nm neodymium: yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;69(4):578–582. doi:10.1016/j.jaad.2013.04.054
   PubMed Web of Science ®Google Scholar
• Souza LWF, Souza SVT, Botelho A. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol. 2014;89:184–186. doi:10.1590/abd1806-4841.20142197
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216. doi:10.2340/00015555-0811
   PubMed Web of Science ®Google Scholar
• Xu Z-L, Xu J, Zhuo F, et al. Effects of laser irradiation on Trichophyton rubrum growth and ultrastructure. Chin Med J. 2012;125(20):3697–3700.
   PubMed Web of Science ®Google Scholar
• Fonda-Pascual P, Moreno-Arrones OM, Alegre-Sanchez A, et al. In situ production of ROS in the skin by photodynamic therapy as a powerful tool in clinical dermatology. Methods. 2016;109:190–202. doi:10.1016/j.ymeth.2016.07.008
   PubMed Web of Science ®Google Scholar
• Bulson JM, Liveris D, Derkatch I, et al. Non‐thermal atmospheric plasma treatment of onychomycosis in an in vitro human nail model. Mycoses. 2020;63(2):225–232. doi:10.1111/myc.13030
   PubMed Web of Science ®Google Scholar
• Lipner S, Friedman G, Scher R. Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin Exp Dermatol. 2017;42(3):295–298. doi:10.1111/ced.12973
   PubMed Web of Science ®Google Scholar
• Ouf SA, El-Adly AA, Mohamed -A-AH. Inhibitory effect of silver nanoparticles mediated by atmospheric pressure air cold plasma jet against dermatophyte fungi. J Med Microbiol. 2015;64(10):1151–1161. doi:10.1099/jmm.0.000133
   PubMed Web of Science ®Google Scholar
• Lux J, Dobiáš R, Kuklová I, et al. Inactivation of dermatophytes causing onychomycosis and Its therapy using non-thermal plasma. J Fungi. 2020;6(4):214. doi:10.3390/jof6040214
   Web of Science ®Google Scholar
• Shemer A, Gupta A, Amichai B, et al. An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. J Dermatological Treatment. 2016;27(5):480–483. doi:10.3109/09546634.2016.1151856
   PubMed Web of Science ®Google Scholar
• Polak A. The past, present and future of antimycotic combination therapy. Mycoses. 1999;42(5‐6):355–370. doi:10.1046/j.1439-0507.1999.00475.x
   PubMed Web of Science ®Google Scholar
• Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. Indian Dermatol Online J. 2017;8(5):310. doi:10.4103/idoj.IDOJ_169_17
   PubMedGoogle Scholar
• Gupta AK, Paquet M. Systemic antifungals to treat onychomycosis in children: a systematic review. Pediatr Dermatol. 2013;30(3):294–302. doi:10.1111/pde.12048
   PubMed Web of Science ®Google Scholar
• Gupta AK, Venkataraman M, Shear NH, et al. Onychomycosis in children–review on treatment and management strategies. J Dermatological Treatment. 2020;5:1–12.
   Google Scholar
• Ginter‐Hanselmayer G, Weger W, Smolle J. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients. J Eur Acad Dermatol Venereol. 2008;22(4):470–475. doi:10.1111/j.1468-3083.2007.02498.x
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Stubb S. Onychomycosis in children: treatment results of forty-seven patients. Acta Derm Venereol. 2002;82(6):484–485. doi:10.1080/000155502762064764
   PubMed Web of Science ®Google Scholar
• Gupta AK, Nolting S, de Prost Y, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology. 1999;199(3):248–252. doi:10.1159/000018256
   PubMed Web of Science ®Google Scholar
• Gupta AK, Mays RR, Versteeg SG, et al. Onychomycosis in children: safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35(5):552–559. doi:10.1111/pde.13561
   PubMed Web of Science ®Google Scholar
• Gupta AK, Chang P, Del Rosso JQ, et al. PHARMACOLOGY AND THERAPEUTICS: onychomycosis in Children: prevalence and Management. Pediatr Dermatol. 1998;15(6):464–471. doi:10.1046/j.1525-1470.1998.1998015464.x
   PubMed Web of Science ®Google Scholar
• Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol. 1996;35(2):216–219. doi:10.1016/S0190-9622(96)90327-8
   PubMed Web of Science ®Google Scholar
• Friedlander SF, Chan YC, Chan YH, et al. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol. 2013;30(3):316–322. doi:10.1111/pde.12064
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Elewski B, Sugarman JL, et al. Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: open-label phase 4 study. J Am Acad Dermatol. 2021;84(4):1140–1142. doi:10.1016/j.jaad.2020.06.1004
   PubMed Web of Science ®Google Scholar
• Rich P, Spellman M, Purohit V, et al. Tavaborole 5% topical solution for the treatment of toenail onychomycosis in pediatric patients: results from a phase 4 open-label study. J Drugs Dermatol. 2019;18(2):190–195.
   PubMed Web of Science ®Google Scholar
• Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in improving results in ONychomycosis-concomitant lamisil® and debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4(1):1–13. doi:10.1016/j.amjopharm.2005.12.012
   PubMedGoogle Scholar
• Iozumi K, Abe M, Ito Y, et al. Efficacy of long‐term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: a multicenter, single‐arm study. J Dermatol. 2019;46(8):641–651. doi:10.1111/1346-8138.14935
   PubMed Web of Science ®Google Scholar
• Loo DS. Onychomycosis in the elderly. Drugs Aging. 2007;24(4):293–302. doi:10.2165/00002512-200724040-00003
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals. Jublia (Efinaconazole) Topical Solution, 10% [Package Insert]. Bridgewater, NJ: Valeant Pharmaceuticals; 2014. Available from http://www.valeant.com/Portals/25/Pdf/PI/Jublia-PI.pdf. Accessed September 9, 2022.
   Google Scholar
• Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010;62(3):411–414. doi:10.1016/j.jaad.2009.04.062
   PubMed Web of Science ®Google Scholar
• Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother. 2012;13(8):1131–1142. doi:10.1517/14656566.2012.681779
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini B, Stinchi C, et al. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology. 1998;197(2):162–166. doi:10.1159/000017990
   PubMed Web of Science ®Google Scholar
• Tosti A, Elewski BE. Onychomycosis: practical approaches to minimize relapse and recurrence. Skin Appendage Disorders. 2016;2(1–2):83–87. doi:10.1159/000448056
   PubMed Web of Science ®Google Scholar
• Shemer A, Gupta AK, Kamshov A, et al. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatol Ther. 2017;30(5):e12545. doi:10.1111/dth.12545
   Web of Science ®Google Scholar
• Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15(3):279–282.
   PubMedGoogle Scholar
• Feuilhade de Chauvin M. A study on the decontamination of insoles colonized by Trichophyton rubrum: effect of terbinafine spray powder 1% and terbinafine spray solution 1%. J Eur Acad Dermatol Venereol. 2012;26(7):875–878. doi:10.1111/j.1468-3083.2011.04176.x
   PubMed Web of Science ®Google Scholar
• Gupta AK, Brintnell WC. Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis? J Cutan Med Surg. 2013;17(4):243–249. doi:10.2310/7750.2012.12068
   PubMed Web of Science ®Google Scholar
• Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171(1):43–49. doi:10.1007/s11046-010-9347-9
   PubMed Web of Science ®Google Scholar
• Velasquez-Agudelo V, Cardona-Arias JA. Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis. BMC Infect Dis. 2017;17(1):1–11. doi:10.1186/s12879-017-2258-3
   PubMed Web of Science ®Google Scholar
• Lim SS, Ohn J, Mun J-H. Diagnosis of onychomycosis: from conventional techniques and dermoscopy to artificial intelligence. Front Med. 2021;8:637216. doi:10.3389/fmed.2021.637216
   Web of Science ®Google Scholar